Orexigen updated the projected timeframe for completion of enrollment of the Light Study, the Contrave cardiovascular outcomes clinical trial. Orexigen now expects to complete enrollment of patients required for the interim analysis of the Light Study in Q1 2013, potentially reducing by half the original projections. The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events during randomized treatment for Contrave compared to placebo.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?